(1) Symbolism and stigma of injectable diabetes treatment; (2) administration and device preferences; (3) treatment convenience and social impact; (4) treatment efficacy and benefits; (5) negative treatment side‐effects. Some participants were more receptive to insulin therapy following GLP‐1RA use, others emphasised unique concerns about insulin. This evidence concerns the gene INS and diabetes mellitus.